Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2009 Dec 16:9:34.
doi: 10.1186/1472-6874-9-34.

The overdiagnosis nightmare: a time for caution

Stefano Ciatto  1
Affiliations
Editorial

The overdiagnosis nightmare: a time for caution

Stefano Ciatto. BMC Womens Health. .

Abstract

Overdiagnosis (and overtreatment) of cancers not bound to become symptomatic during lifetime is an unavoidable drawback of mammography screening. The magnitude of overdiagnosis has been estimated to be in the range of 5-10%, and thus acceptable in view of screening benefits as to reduced mortality. In a recent research article in BMC Women's Health, Jørgensen, Zahl and Gøtzsche suggest that overdiagnosis may be as high as 33%, based on their analysis of breast cancer incidence in screened and non-screened areas in Denmark. Here we consider how reliable such analyses can be, why it might have been useful to adjust comparisons between screened and non-screened areas for early detection lead time, and what further evidence might be needed to build on or confirm these results.

PubMed Disclaimer

Comment on

References

    1. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organized mammography screening programmes: Systematic review of incidence trends. Br Med J. 2009;339:b2587. doi: 10.1136/bmj.b2587. - DOI - PMC - PubMed
    1. Perry NM, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth. Luxembourg: European Commission; 2006. - PubMed
    1. Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol. 1980;14:29–43. - PubMed
    1. Draisma G, Boer R, Otto SJ, Cruijsen IW van der, Damhuis RA, Schröder FH. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:868–78. - PubMed
    1. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–8. doi: 10.1056/NEJMoa0810084. - DOI - PubMed